Hot Investor Mandate: Venture Capital Firm Focuses on Europe-Based Therapeutics Investment Opportunities, Open to Assets from Pre-Clinical Development to Phase II

8 Jul

A venture capital firm with its newest fund closed in 2020, focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: